ANIP
ANI Pharmaceuticals, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
动量输入(同类管理人):
持有人广度 +30.0% ·
股份流向 +3.1% ·
净新建仓位 +20.0%
· 公式
广泛增持:持股数量上升,持有人数量增加
所有持股数据:仅限已追踪的 13F 管理人,普通股持仓,报告期 Q3 2025
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 15.90K | $1.15M | n/a | n/a |
| Q2 2026 | 100 | +1 | 15.23M | $1.21B | +7 | −7 |
| Q1 2026 | 103 | -4 | 30.24M | $1.11B | +4 | −9 |
| Q4 2025 | 108 | 0 | 15.43M | $1.15B | +1 | n/a |
| Q3 2025 | 20 | +5 | 7.92M | $725.10M | +5 | −1 |
| Q2 2025 | 13 | -1 | 6.82M | $445.05M | n/a | −1 |
| Q1 2025 | 11 | +3 | 3.19M | $213.52M | +3 | n/a |
| Q4 2024 | 8 | -2 | 3.16M | $174.48M | n/a | −2 |
| Q3 2024 | 9 | -3 | 1.88M | $111.88M | n/a | −3 |
| Q2 2024 | 12 | n/a | 1.26M | $80.52M | n/a | n/a |
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (被动) | 2.55M | -1.2% | $233.48M | 0.0% | ▼ Trim | 2 | SEC ↗ ×16 |
| 2 | The Vanguard Group ✦ (被动) | 1.28M | 0.0% | $117.02M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 3 | State Street Global Advisors ✦ (被动) | 711.71K | -0.6% | $65.19M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 4 | Citadel Advisors ✦ | 580.09K | +1.8% | $53.14M | 0.0% | ▲ Add | 6 | SEC ↗ ×3 |
| 5 | Geode Capital Management ✦ (被动) | 458.01K | +7.1% | $41.96M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 6 | Point72 Asset Management ✦ | 399.09K | 新增 | $36.56M | 0.1% | New | 1 | SEC ↗ |
| 7 | Goldman Sachs Group ✦ | 379.03K | n/a | $34.72M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 8 | Arrowstreet Capital ✦ | 360.18K | 新增 | $32.99M | 0.0% | New | 1 | SEC ↗ |
| 9 | Renaissance Technologies ✦ | 272.90K | +112.6% | $25.00M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 10 | JPMorgan Chase ✦ | 258.19K | n/a | $23.65M | 0.0% | n/c | 1 | SEC ↗ ×10 |
| 11 | Morgan Stanley ✦ | 232.03K | n/a | $21.25M | 0.0% | n/c | 1 | SEC ↗ ×10 |
| 12 | D. E. Shaw & Co. ✦ | 213.01K | +211.9% | $19.51M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 13 | Millennium Management ✦ | 65.25K | -93.5% | $5.98M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 14 | Two Sigma Investments ✦ | 53.78K | 新增 | $4.93M | 0.0% | New | 1 | SEC ↗ |
| 15 | Fidelity (FMR) ✦ | 35.09K | +865.5% | $3.21M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 16 | Marshall Wace ✦ | 30.19K | 新增 | $2.77M | 0.0% | New | 1 | SEC ↗ ×2 |
| 17 | AQR Capital Management ✦ | 14.48K | -22.1% | $1.33M | 0.0% | ▼ Trim | 6 | SEC ↗ ×4 |
| 18 | T. Rowe Price ✦ | 9.70K | +5.2% | $889,000 | 0.0% | ▲ Add | 6 | SEC ↗ |
| 19 | Gotham Asset Management ✦ | 8.59K | 新增 | $786,661 | 0.0% | New | 1 | SEC ↗ |
| 20 | Wellington Management ✦ | 8.17K | +3.7% | $748,556 | 0.0% | ▲ Add | 3 | SEC ↗ ×4 |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例,即持仓信心指标。✦ = 精选管理人。
新增买入方
| Point72 Asset Management | $36.56M | 0.1% |
| Arrowstreet Capital | $32.99M | 0.0% |
| Two Sigma Investments | $4.93M | 0.0% |
| Marshall Wace | $2.77M | 0.0% |
| Gotham Asset Management | $786,661 | 0.0% |
已清仓
| Norges Bank | $625,421 | 曾为 0.0% |
全市场背景: 涵盖所有13F申报机构(SEC结构化数据, Q1 2026): 4 持有人, 27.49M 股份, $50.55M 已申报. 这是与上方被追踪全域数据不同的较早期间,两者从不混用。
持有该证券的受追踪机构最常同时持有的其他证券:基于共同持有计数,而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Officer, Director · 5.40K 股 · $388,206
Officer · 500 股 · $36,795
Officer · 2.85K 股 · $208,050
Officer, Director · 5.40K 股 · $383,400
Officer · 500 股 · $35,395
Director · 1.00K 股 · $71,530
Officer · 2.85K 股 · $207,480
Officer, Director · 5.40K 股 · $401,220
Officer · 500 股 · $37,740
Officer · 3.16K 股 · $243,474
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论